{"id":2847,"date":"2014-07-08T12:29:02","date_gmt":"2014-07-08T17:29:02","guid":{"rendered":"https:\/\/fomatmedical.com\/?p=2847"},"modified":"2026-05-08T00:01:30","modified_gmt":"2026-05-08T07:01:30","slug":"alzheimers-drug-development-pipeline","status":"publish","type":"post","link":"https:\/\/fomatmedical.com\/es\/blogs-updates\/alzheimers-drug-development-pipeline\/","title":{"rendered":"Un estudio afirma que el 99,1 % de los ensayos cl\u00ednicos de medicamentos contra el Alzheimer fracasan."},"content":{"rendered":"
\n
\n
\n
\n
\n
\n
\n

Alzheimers Drug Development Pipeline Faces a 99.6% Failure Rate<\/h3>\n

A landmark analysis from researchers at the Cleveland Clinic<\/a> Lou Ruvo Center for Brain Health has exposed a critical vulnerability in the fight against Alzheimer’s disease. After examining every clinical trial conducted over a decade, from 2002 to 2012, the team found that the Alzheimers drug development pipeline carries a failure rate of 99.6 percent. The findings, published in the journal Alzheimer’s Research and Therapy, paint a sobering picture of where research currently stands and what must change.<\/p>\n

With an estimated 44 million people living with Alzheimer’s disease worldwide, the stakes could not be higher. Yet the Alzheimers drug development pipeline has been shrinking since 2009, and the overall number of candidates moving through development remains dangerously low.<\/p>\n

What the Analysis Revealed About the Alzheimers Drug Development Pipeline<\/h3>\n

The research team, led by Jeffrey Cummings, director of the Cleveland Clinic Lou Ruvo Center for Brain Health, used the advanced search tools of ClinicalTrials.gov to build a comprehensive review of all active and completed trials since 2002. Joining Cummings were Kate Zhong, senior director of clinical research and development, and Travis Morstorf, a medical student at Touro University.<\/p>\n

Their goal was not simply to count failures but to understand why Alzheimer’s drug development so consistently falls short. What they found was a system under strain. Investment in new agents is low relative to the scale of the disease. The attrition rate at each phase of development is severe. And the pipeline, rather than growing to meet the challenge, has been contracting year over year.<\/p>\n

The economic dimension makes the situation even more urgent. Alzheimer’s disease costs the United States economy more than cardiovascular disease or cancer combined, yet the research infrastructure supporting the Alzheimers drug development pipeline has not grown proportionally to match that burden. Researchers concluded that the system must be supported, grown, and coordinated if the success rate is to improve.<\/p>\n

Why Drug Repositioning Could Strengthen the Pipeline<\/h3>\n

One potential path forward for the Alzheimers drug development pipeline is drug repositioning, also called repurposing. This approach involves studying a compound already approved by the FDA for one condition and evaluating whether it may also be effective for Alzheimer’s disease. Because the safety profile of repositioned drugs is already established, this strategy can reduce the time and cost associated with early phase development.<\/p>\n

A concrete example is the Phase 2a clinical trial being led by the Cleveland Clinic Lou Ruvo Center for Brain Health to evaluate bexarotene, a drug currently approved to treat skin cancer, as a potential Alzheimer’s therapy. Earlier animal studies showed that bexarotene was able to reduce the protein buildup in the brain associated with the disease, specifically the amyloid plaques that are a hallmark of Alzheimer’s pathology.<\/p>\n

If bexarotene demonstrates efficacy in the human trial, it would represent a significant proof of concept for the repositioning model and could encourage similar investigations of other existing compounds across the Alzheimers drug development pipeline.<\/p>\n

The System Needs More Support and Coordination<\/h3>\n

Increasing the number of compounds entering the pipeline is not enough on its own. The infrastructure supporting Alzheimer’s drug development, including funding structures, regulatory pathways, and trial design, must also be strengthened and better coordinated.<\/p>\n

Failure in clinical trials is not unique to Alzheimer’s research, but the rate at which candidates are lost in this disease area is unusually high. Improving that rate requires not only more investment in novel drug discovery but also a systematic effort to study repositioning candidates, share data across institutions, and design trials that generate meaningful insights even when a compound does not advance.<\/p>\n

Cummings noted that understanding the historical patterns of failure is an essential first step. Without a clear picture of where the Alzheimers drug development pipeline breaks down at each phase, it is difficult to target interventions that could improve outcomes across the board.<\/p>\n

What This Means for the Future of Alzheimer’s Research<\/h3>\n

The Cleveland Clinic analysis serves as both a diagnosis and a call to action. The Alzheimers drug development pipeline is not producing treatments at a pace that matches the global burden of the disease. Addressing that gap will require sustained investment, creative approaches to trial design, and a willingness to look beyond entirely new compounds toward the potential that already approved drugs may hold.<\/p>\n

For clinical research organizations and sponsors working in neurology, this landscape represents both a significant challenge and a meaningful opportunity. FOMAT conducts Phase I through Phase IV studies across a range of therapeutic areas, supporting the kind of research that advances the understanding of diseases like Alzheimer’s. Learn more about our physician investigator network<\/a> or explore our active studies<\/a>.<\/p>\n

For more updates on clinical research and neurology trials, visit the FOMAT blog<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

La cartera de medicamentos en desarrollo contra el Alzheimer se enfrenta a una tasa de fracaso del 99,61 % Un an\u00e1lisis hist\u00f3rico realizado por investigadores del Centro Lou Ruvo para la Salud Cerebral de la Cl\u00ednica Cleveland ha puesto de manifiesto una vulnerabilidad cr\u00edtica en la lucha contra la enfermedad de Alzheimer. Tras examinar todos los ensayos cl\u00ednicos realizados\u2026<\/p>","protected":false},"author":3,"featured_media":111533,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[968],"tags":[1036,1037,1038,903,970,1020,982,906],"class_list":["post-2847","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogs-updates","tag-alzheimer","tag-cleveland","tag-clinic","tag-clinical","tag-disease","tag-researchers","tag-study","tag-trials"],"acf":[],"_links":{"self":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/2847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/comments?post=2847"}],"version-history":[{"count":0,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/2847\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media\/111533"}],"wp:attachment":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media?parent=2847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/categories?post=2847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/tags?post=2847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}